Clinical trial

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

NCT00264849

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Omalizumab Normalized identity: omalizumabView linked drug · Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Optimized asthma therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-11-01

PhasePHASE4

Conditions

Asthmaverified · MONDO: asthma

Interventions

OmalizumabDRUG · verified · RxNorm: omalizumab

Optimized asthma therapyOTHER

Sponsors & collaborators

Novartislead sponsor

Genentech, Inc.collaborator

Tanoxcollaborator

Mapped research locations

MadridSpain1 BerlinGermany1 BudapestHungary1 BrusselsBelgium1 RomaItaly1 StockholmSweden1 AthensGreece1 LodzPoland1 HaifaIsrael1 LisbonPortugal1 DublinIreland1 OsloNorway1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00264849 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.